With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug

Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder.

On Wednesday, New York-based Ovid (NASDAQ: OVID) reported Phase 2 results showing that the molecule, soticlestat, reduced the frequency of epileptic seizures in CDKL5 deficiency disorder (CDD) and chromosome 15q duplication (Dup15q) syndrome. The study was small and was not designed to show statistical significance. But combined with previously reported Phase 2 results in... Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

          

          

            
Author: Frank Vinluan

Source : https://xconomy.com/new-york/2020/09/30/with-phase-2-data-in-hand-ovid-eyes-multiple-fda-filings-for-epilepsy-drug/

Date : 2020-09-30T12:00:46.000Z